| NCT ID | NCT06724562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Fibrodysplasia Ossificans Progressiva (FOP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 11 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 11 participants in total. It began in 2025-04-01 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II study. This study specifically focuses on patients with severe FOP who are being considered by their medical team for rescue therapy with anti-IL1 therapy. Preliminary data suggests patients experience significant decreases in flare frequency when taking anti-IL1 therapy, but other measures of efficacy remain unassessed, such as changes in heterotopic ossification formation, changes in pain medication use, and changes in functionality.
Eligibility Criteria
Inclusion Criteria: * Patients with a clinical presentation consistent with FOP and a genetic diagnosis of classical FOP (ACVR1R206H variant) (2), male or female aged 6-30 years old. * Patients with unusually severe FOP disease activity. This will be determined by FOP flare frequency of \>4 flares per year, which is 2 times higher than the reported average in prior FOP studies ; or by a persistent flare that has failed to resolve after 1 month of standard-of-care therapy. * Patients whose primary medical team has decided that rescue therapy with an anti-IL1 medication should be initiated. Once the primary medical team has decided that anti-IL1 therapy should be pursued, the subject will be told about this clinical-observational study and enrolled in the pre-treatment phase while access to the anti-IL1 therapy is being obtained by the clinical management team. * Ability to participate in all assessments, including blood draws, radiology assessments, and travel. Age 6 is chosen as the lower limit to avoid the need for anesthesia for whole body CT in younger subjects. * No history of unexplained infections, known autoimmune disease, or contraindication to anti-IL1 therapy. * Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Inability to travel to site for assessments * Pre-existing autoimmune or autoinflammatory disease (aside from FOP) * Inability to tolerate assessments (such as phlebotomy) * Unexplained infections * Current participation in an interventional trial, or study of a potentially disease modifying medication * Inability to take medications as prescribed by managing physician
Contact & Investigator
Edward Hsiao, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06724562 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 30 Years, studying Fibrodysplasia Ossificans Progressiva (FOP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06724562 currently recruiting?
Yes, NCT06724562 is actively recruiting participants. Contact the research team at Samantha.klein@ucsf.edu for enrollment information.
Where is the NCT06724562 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06724562 clinical trial?
NCT06724562 is sponsored by University of California, San Francisco. The principal investigator is Edward Hsiao, MD, PhD at University of California, San Francisco. The trial plans to enroll 11 participants.